The purpose of this pilot study is to investigate whether sPD-L1 could potentially be a predictive biomarker in patients with EGFR-mutated (EGFRmut) lung adenocarcinoma treated with EGFR TKIs based on a comparison of sPD-L1 blood levels and clinical outcomes. Here, SPDL1 is linked to lung adenocarcinoma.